당뇨병 기기 시장 규모, 점유율, 성장 및 세계 업계 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of diabetes devices Market

The global diabetes devices market size was valued at USD 35.71 billion in 2025 and is projected to grow from USD 38.77 billion in 2026 to USD 74.73 billion by 2034, exhibiting a CAGR of 8.55% during the forecast period. North America dominated the market with a 40.54% share in 2025. The market is supported by the rising prevalence of diabetes, increasing demand for continuous disease management, technological advancements, and growing adoption of connected monitoring and insulin delivery solutions.

The diabetes devices market includes monitoring and treatment technologies that help patients and healthcare professionals manage diabetes more effectively. Blood glucose monitoring systems, continuous glucose monitoring devices, insulin pumps, insulin pens, and automated delivery systems are increasingly becoming important components of modern diabetes care. The shift from periodic monitoring toward continuous, connected, and personalized management is creating new opportunities for market expansion.

Market Definition and Scope

The diabetes devices market covers medical devices used for diabetes monitoring, diagnosis, treatment, and long-term disease management. The market is analyzed by type, distribution channel, and region. Increasing healthcare expenditure, improved diagnosis, wider reimbursement coverage, and rising awareness of diabetes management are expected to support market growth through 2034.

Market Dynamics

Drivers

Rising Prevalence of Diabetes

The increasing global prevalence of diabetes is a primary factor driving demand for monitoring and treatment devices. Rapid urbanization, sedentary lifestyles, obesity, and changing dietary patterns are contributing to the expanding diabetic population. Growing diagnosis rates are consequently increasing the need for blood glucose monitoring systems and insulin delivery technologies.

Introduction of Advanced Products

Continuous innovation is transforming diabetes management. Connected glucose monitors, smart insulin pumps, wearable devices, insulin patches, and automated insulin delivery platforms are improving patient convenience and treatment effectiveness. Integration with mobile applications and digital health platforms is further encouraging adoption.

Trends

The market is undergoing a shift toward digitalization, automation, and connected diabetes care. Continuous glucose monitoring is becoming an important technology because it provides frequent glucose readings and enables patients and clinicians to identify trends. Artificial intelligence, predictive analytics, cloud connectivity, and mobile applications are increasingly being incorporated into diabetes devices, supporting personalized and data-driven treatment.

Restraints

High development costs, stringent regulatory requirements, reimbursement limitations, and complex manufacturing processes can restrict market expansion. Advanced devices can also have higher upfront costs, which may limit adoption in price-sensitive and developing markets.

Impact of COVID-19

The COVID-19 pandemic disrupted healthcare services and delayed several routine consultations and non-emergency procedures. Supply-chain interruptions also affected the availability of certain medical devices. However, the pandemic increased interest in home-based disease management and remote monitoring. This supported demand for connected diabetes technologies and strengthened the importance of digital healthcare solutions.

Segmentation Analysis

By Type

Based on type, the market is divided into monitoring devices and treatment devices. Monitoring devices represented the leading category, supported by increasing adoption of blood glucose monitoring systems and continuous glucose monitoring technologies. Continuous monitoring offers real-time information and supports better patient self-management.

Treatment devices include insulin pens, insulin pumps, patches, and automated insulin delivery systems. Advanced treatment technologies are gaining traction as patients increasingly seek convenient and personalized methods of insulin administration.

By Distribution Channel

The market is segmented into institutional sales and retail sales. Retail sales are expected to experience strong growth due to the increasing availability of diabetes monitoring products through pharmacies and other retail channels. Institutional sales remain important for advanced devices adopted through hospitals, clinics, and healthcare systems.

Regional Insights

North America

North America maintained its leading position in 2025 due to high diabetes prevalence, advanced healthcare infrastructure, strong reimbursement coverage, and rapid adoption of connected monitoring and insulin delivery technologies. The region benefits from the presence of major manufacturers and significant investment in diabetes-related innovation.

Europe

Europe represents an established market supported by public healthcare systems and increasing adoption of advanced diabetes monitoring technologies. Rising diabetes prevalence and growing awareness of disease management are expected to sustain regional demand.

Asia Pacific

Asia Pacific is expected to register the fastest growth through 2034. Rising diabetes prevalence, urbanization, improving healthcare infrastructure, and increasing adoption of technologically advanced monitoring and treatment devices are creating significant opportunities across China, India, Japan, and other countries.

Latin America, Middle East & Africa

These regions are expected to experience gradual expansion as diagnosis rates improve, healthcare infrastructure develops, and awareness of diabetes management increases. Increasing investment in healthcare systems will support long-term adoption.

Competitive Landscape

The diabetes devices market is highly competitive, with leading companies focusing on product innovation, connected technologies, strategic partnerships, and geographic expansion. Key companies include F. Hoffmann-La Roche Ltd., Tandem Diabetes Care, Inc., B. Braun Melsungen AG, Medtronic, BD, Novo Nordisk A/S, Abbott, and Sanofi. Companies are increasingly developing integrated ecosystems combining hardware, software, analytics, and digital health services.

Innovation and Growth Opportunities

Innovation in sensor accuracy, miniaturization, interoperability, artificial intelligence, and automated insulin delivery will remain central to future market development. Continuous glucose monitoring and closed-loop insulin delivery systems offer significant growth potential. Emerging markets also provide opportunities as diagnosis and healthcare access improve. Companies capable of combining affordability, connectivity, clinical effectiveness, and ease of use are likely to strengthen their competitive position.

Report Coverage

The diabetes devices market report provides comprehensive analysis of market size, market value, growth drivers, trends, restraints, segmentation, regional performance, competitive landscape, technological developments, and industry opportunities. The report evaluates monitoring and treatment devices across institutional and retail distribution channels and examines developments across major global regions.

Conclusion

The global diabetes devices market is expected to expand from USD 35.71 billion in 2025 to USD 38.77 billion in 2026 and USD 74.73 billion by 2034. Rising diabetes prevalence, increasing demand for continuous monitoring, technological advancements, and the integration of devices with digital healthcare platforms will remain major growth factors. North America will continue to represent a strong market, while Asia Pacific is positioned as a major growth opportunity. The transition toward connected, automated, and personalized diabetes management is expected to define the industry's development through 2034.

Unit Value (USD billion)

Segmentation By Type

• Blood Glucose Monitoring Systems
  • Continuous Glucose Monitoring Systems
  • Self-Monitoring Blood Glucose Systems
• Treatment Devices
  • Insulin Pens
  • Insulin Pumps
  • Insulin Jet Injectors
  • Insulin Syringes
  • Others

By Distribution Channel

• Institutional Sales
• Retail Sales

By Geography

• North America (U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia Pacific)
• Latin America (Brazil, Mexico, and the Rest of Latin America)
• Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence and Incidence of Diabetes by Key Countries
• 4.2. Technological Advancements
• 4.3. Pricing Analysis, by Key Market Players/ Key Regions
• 4.4. Recent Industry Developments Such As Mergers & Acquisitions

5. Global Diabetes Devices Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast- By Type
  • 5.2.1. Blood Glucose Monitoring Systems
    • 5.2.1.1. Continuous Glucose Monitoring Systems
    • 5.2.1.2. Self-Monitoring Blood Glucose Systems
  • 5.2.2. Treatment Devices
    • 5.2.2.1. Insulin Pens
    • 5.2.2.2. Insulin Pumps
    • 5.2.2.3. Insulin Jet Injectors
    • 5.2.2.4. Insulin Syringes
    • 5.2.2.5. Others
• 5.3. Market Analysis, Insights and Forecast- By Distribution Channel
  • 5.3.1. Institutional Sales
  • 5.3.2. Retail Sales
• 5.4. Market Analysis, Insights and Forecast- By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Diabetes Devices Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis, Insights and Forecast - By Type
  • 6.2.1. Blood Glucose Monitoring Systems
    • 6.2.1.1. Continuous Glucose Monitoring Systems
    • 6.2.1.2. Self-Monitoring Blood Glucose Systems
  • 6.2.2. Treatment Devices
    • 6.2.2.1. Insulin Pens
    • 6.2.2.2. Insulin Pumps
    • 6.2.2.3. Insulin Jet Injectors
    • 6.2.2.4. Insulin Syringes
    • 6.2.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Institutional Sales
  • 6.3.2. Retail Sales
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Diabetes Devices Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis, Insights and Forecast - By Type
  • 7.2.1. Blood Glucose Monitoring Systems
    • 7.2.1.1. Continuous Glucose Monitoring Systems
    • 7.2.1.2. Self-Monitoring Blood Glucose Systems
  • 7.2.2. Treatment Devices
    • 7.2.2.1. Insulin Pens
    • 7.2.2.2. Insulin Pumps
    • 7.2.2.3. Insulin Jet Injectors
    • 7.2.2.4. Insulin Syringes
    • 7.2.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Institutional Sales
  • 7.3.2. Retail Sales
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. Spain
  • 7.4.4. Italy
  • 7.4.5. Scandinavia
  • 7.4.6. France
  • 7.4.7. Rest of Europe

8. Asia Pacific Diabetes Devices Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis, Insights and Forecast - By Type
  • 8.2.1. Blood Glucose Monitoring Systems
    • 8.2.1.1. Continuous Glucose Monitoring Systems
    • 8.2.1.2. Self-Monitoring Blood Glucose Systems
  • 8.2.2. Treatment Devices
    • 8.2.2.1. Insulin Pens
    • 8.2.2.2. Insulin Pumps
    • 8.2.2.3. Insulin Jet Injectors
    • 8.2.2.4. Insulin Syringes
    • 8.2.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Institutional Sales
  • 8.3.2. Retail Sales
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. China
  • 8.4.2. India
  • 8.4.3. Australia
  • 8.4.4. Japan
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Diabetes Devices Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis, Insights and Forecast - By Type
  • 9.2.1. Blood Glucose Monitoring Systems
    • 9.2.1.1. Continuous Glucose Monitoring Systems
    • 9.2.1.2. Self-Monitoring Blood Glucose Systems
  • 9.2.2. Treatment Devices
    • 9.2.2.1. Insulin Pens
    • 9.2.2.2. Insulin Pumps
    • 9.2.2.3. Insulin Jet Injectors
    • 9.2.2.4. Insulin Syringes
    • 9.2.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Institutional Sales
  • 9.3.2. Retail Sales
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Diabetes Devices Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis, Insights and Forecast - By Type
  • 10.2.1. Blood Glucose Monitoring Systems
    • 10.2.1.1. Continuous Glucose Monitoring Systems
    • 10.2.1.2. Self-Monitoring Blood Glucose Systems
  • 10.2.2. Treatment Devices
    • 10.2.2.1. Insulin Pens
    • 10.2.2.2. Insulin Pumps
    • 10.2.2.3. Insulin Jet Injectors
    • 10.2.2.4. Insulin Syringes
    • 10.2.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Institutional Sales
  • 10.3.2. Retail Sales
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. South Africa
  • 10.4.2. GCC
  • 10.4.3. Rest of Middle East and Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2021)
• 11.3. Company Profiles
  • 11.3.1. F. Hoffmann-La Roche Ltd.
    • 11.3.1.1. Overview,
    • 11.3.1.2. Types & services,
    • 11.3.1.3. SWOT analysis,
    • 11.3.1.4. Recent developments,
    • 11.3.1.5. strategies,
    • 11.3.1.6. financials (based on availability)
  • 11.3.2. Tandem Diabetes Care, Inc.
    • 11.3.2.1. Overview,
    • 11.3.2.2. Types & services,
    • 11.3.2.3. SWOT analysis,
    • 11.3.2.4. Recent developments,
    • 11.3.2.5. strategies,
    • 11.3.2.6. financials (based on availability)
  • 11.3.3. B. Braun Melsungen AG
    • 11.3.3.1. Overview,
    • 11.3.3.2. Types & services,
    • 11.3.3.3. SWOT analysis,
    • 11.3.3.4. Recent developments,
    • 11.3.3.5. strategies,
    • 11.3.3.6. financials (based on availability)
  • 11.3.4. Medtronic
    • 11.3.4.1. Overview,
    • 11.3.4.2. Types & services,
    • 11.3.4.3. SWOT analysis,
    • 11.3.4.4. Recent developments,
    • 11.3.4.5. strategies,
    • 11.3.4.6. financials (based on availability)
  • 11.3.5. BD
    • 11.3.5.1. Overview,
    • 11.3.5.2. Types & services,
    • 11.3.5.3. SWOT analysis,
    • 11.3.5.4. Recent developments,
    • 11.3.5.5. strategies,
    • 11.3.5.6. financials (based on availability)
  • 11.3.6. Novo Nordisk A/S
    • 11.3.6.1. Overview,
    • 11.3.6.2. Types & services,
    • 11.3.6.3. SWOT analysis,
    • 11.3.6.4. Recent developments,
    • 11.3.6.5. strategies,
    • 11.3.6.6. financials (based on availability)
  • 11.3.7. Abbott
    • 11.3.7.1. Overview,
    • 11.3.7.2. Types & services,
    • 11.3.7.3. SWOT analysis,
    • 11.3.7.4. Recent developments,
    • 11.3.7.5. strategies,
    • 11.3.7.6. financials (based on availability)
  • 11.3.8. Other Prominent Players
    • 11.3.8.1. Overview,
    • 11.3.8.2. Types & services,
    • 11.3.8.3. SWOT analysis,
    • 11.3.8.4. Recent developments,
    • 11.3.8.5. strategies,
    • 11.3.8.6. financials (based on availability)

12. Strategic Recommendations